 Ampio Pharmaceuticals, Inc. is a non-revenue producing biopharmaceutical company aiming to develop immunology-based therapies for inflammatory conditions. Ampios pipeline consists of one late-stage therapeutic Ampion across six inflammatory indications. Ampion is a novel biologic drug that regulates immune responses by suppressing inflammatory cytokines proteins and activating anti-inflammatory cytokinestissue repair. 